| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
109,450 | 50,337 | 22,894 | 19,594 | 7,148 | ||
Selling, general, and administrative | ||||||
36,550 | 28,080 | 9,518 | 6,311 | 3,425 | ||
Total operating expenses | ||||||
146,000 | 78,417 | 32,412 | 25,905 | 10,573 | ||
Loss from operations | ||||||
-146,000 | -78,417 | -32,412 | -25,905 | -10,573 | ||
Other income (expense): | ||||||
Revaluation of Series A Investor Instrument and Series A Investor Right/Obligation | ||||||
- | - | -1,863 | - | -500 | ||
Interest income, net | ||||||
5,271 | 4,353 | 566 | 33 | - | ||
Total other income, net | ||||||
5,271 | 4,353 | -1,297 | 33 | -500 | ||
Net loss | ||||||
-140,729 | -74,064 | -33,709 | -25,872 | -11,073 | ||
Net loss attributable to common stockholders | ||||||
-140,729 | -74,064 | -37,582 | -29,074 | -12,000 | ||
Net loss per share attributable to common stockholders, basic and diluted | ||||||
-3.86 | -2.39 | -2.83 | -2.85 | -1.18 | ||
Weighted-average common shares outstanding, basic and diluted | ||||||
36,422 | 31,004 | 13,267 | 10,196 | 10,196 | ||
Other comprehensive loss: | ||||||
Net loss | ||||||
-140,729 | -74,064 | -33,709 | - | - | ||
Unrealized gain on marketable securities | ||||||
144 | 8 | -141 | - | - | ||
Comprehensive loss | ||||||
-140,585 | -74,064 | -33,709 | - | - | ||